Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
Beta-thalassemias and hemoglobinopathies are serious inherited blood diseases caused by abnormal or deficiency of beta A chains of hemoglobin, the protein in red blood cells which delivers oxygen throughout the body.
2 United States sites
1 Canada site
> 18 Years
Phase 1/Phase 2
The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.
9 United States sites
9 Brazil sites
6 United Kingdom sites
5 Italy sites
5 Germany sites
5 Belgium sites
4 Spain sites
3 Netherlands sites
3 Colombia sites
3 Greece sites
3 France sites
3 India sites
2 Panama sites
2 Canada sites
2 Lebanon sites
2 Turkey sites
1 South Africa site
1 Kenya site
1 United Arab Emirates site
1 Finland site
1 Ghana site
1 Jordan site
1 Oman site
> 12 Years
Phase 3
The iPeer2Peer Sickle Cell Disease (SCD) study matches youth (12-18 years of age) with SCD to a mentor (trained young adult) who has learned to manage their SCD well, transitioned to adult care, and can support youth participants emotionally and socially.
3 Canada sites
1 United States site
12 to 18 Years
N/A
Folic acid supplementation (1mg/d) is the standard recommendation for Canadian children with Sickle cell disease (SCD), even though it can provide up to six times the recommended intake amount for healthy children.
1 Canada site
2 to 19 Years
N/A
This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD).
4 United States sites
2 Canada sites
2 to 25 Years
hemoglobin SS, hemoglobin SC
Phase 2
This is a single-arm, open-label, multi-site, single-dose Phase 1/2 study in subjects with severe sickle cell disease (SCD).
8 United States sites
1 Belgium site
1 Canada site
1 Germany site
1 Italy site
1 United Kingdom site
12 to 35 Years
Phase 1/Phase 2
The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor.
1 Canada site
1 to 19 Years
HbSS, HbSC
Phase 2
The Lung Clearance Index, measured by multiple breath washout, is a measure of lung function that is considered a research tool in Canada as the device used to measure it is not approved by Health Canada.
1 Canada site
30 to 30 Years
